{"id":54126,"date":"2024-12-20T11:36:20","date_gmt":"2024-12-20T11:36:20","guid":{"rendered":"https:\/\/www.innovationnewsnetwork.com\/?p=54126"},"modified":"2024-12-20T11:36:20","modified_gmt":"2024-12-20T11:36:20","slug":"dr-elias-theodorou-joins-defence-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.innovationnewsnetwork.com\/dr-elias-theodorou-joins-defence-board-of-directors\/54126\/","title":{"rendered":"Dr Elias Theodorou joins Defence board of directors"},"content":{"rendered":"
Dr Elias Theodorou, PhD, is a molecular biologist with over 25 years of experience in cancer research, stem cell differentiation, and gene delivery.<\/p>\n
He is the Chief Scientific Officer and co-founder of Protos Biologics Inc., where he has developed innovative DNA delivery systems.<\/p>\n
Previously, he served as the Director of Research at WBC Biosciences LLC, where he co-invented a method to modify innate immune cells for enhanced anticancer properties.<\/p>\n
Dr Theodorou has held leadership roles at ATUM Inc. and Metagenomix Inc., significantly advancing molecular biology tools and inventing novel methods for drug screening.<\/p>\n
He earned his PhD from Yale University, focusing on identifying novel drivers of neural differentiation. He has also authored numerous publications and holds patents related to gene therapy and protein engineering.<\/p>\n
S\u00e9bastien Plouffe, President, CEO and Founder of Defence Therapeutics, commented: \u201cWith his vast experience in gene and payload delivery, we are grateful to welcome Dr Elias Theodorou to our board of directors.<\/p>\n
\u201cDr Theodorou is a strong molecular research scientist who will bring overall guidance for Defence\u2019s development, mainly in the USA, due to his extensive knowledge, involvement and leadership roles with successful US biotech companies.\u201d<\/p>\n